News | Page 8 | Englander Institute for Precision Medicine

Unusual tumor cells may be overlooked factors in advanced breast cancer

March 12, 2026

An enigmatic type of circulating tumor cell called a dual-positive (DP) cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.

The findings highlight the potential importance of these under-studied cells in breast cancer progression.

Circulating tumors cells are breakaway tumor cells that can seed secondary tumors (...

Pictured above are prostate cancer cells treated with a chemotherapy taxane drug labled with green fluorescence. The drug binds to and stablizes microtubules inside the cells, triggering cell death. Credit: Giannakakou Lab

Study Identifies Gene Linked to Chemotherapy Resistance in Prostate Cancer

March 10, 2026

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel Deaconess Medical Center. The findings provide important new insights into why patients with metastatic disease often stop responding to a key class of life-...

EIPM Researcher Selected for Prostate Cancer Foundation Challenge Award!

March 4, 2026

Dr. Ekta Khurana, an associate professor of systems and computational biomedicine at Weill Cornell Medicine, has received a two-year, $1 million Challenge Award from the Prostate Cancer Foundation to work with researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center on an AI-based method for early detection of...